SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT)
Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission
- Duration
- 14/05/2020 - 30/08/2020
- Coordinator
- Carlos Chaccour
- Funded by
- ISGlobal, Clinica Universidad de Navarra, IDIFARMA
- Website
- http://www.saintproject.org/
Ivermectin is a widely used drug for the treatment and control of certain neglected tropical diseases. The drug has an excellent safety profile, with more than 2.5 billion doses distributed in the last 30 years. It has proven activity against SARS-CoV-2 in vitro.
For this pilot trial we propose to test the potential of ivermectin to reduce the transmission of the virus. If the results are positive this could be quickly scaled given the known safety profile and robust drug supply.
Help Us Do Research on COVID-19!
If you suspect you might have COVID-19, and:
- you have symptoms compatible with the disease within the last 48 hours, such as fever, dry cough, headache, and general malaise;
- you are between 18 and 59 years old; and
- you live in the Pamplona Basin.
Please, call to the telephone number 628 659 003. In case you are a potential candidate, we will lead you to the ER of the Clínica Universidad de Navarra for a formal visit.
We will stop the new coronavirus together!
More Information:
A Project by:
Supported by:
Our Team
Project Coordinator
- Carlos Javier Chaccour
ISGlobal Team
-
Nelly Regina Rabinovich Director of the Malaria Elimination Initiative -
Carlota Dobaño Research Professor -
Gemma Moncunill Assistant Research Professor -
Mary-Ann Richardson BOHEMIA Clinical Trial Manager -
Paula Ruiz-Castillo Postdoctoral Fellow -
Aina Casellas Técnico de Soporte Estadístico
Other projects
See Past ProjectsCOMBACTE
Combating Bacterial Resistance In Europe
Evaluation of Strategies for Yaws Eradication
Yaws eradication
http://pian.isglobal.orgNovel Marine Biomolecules against Biofilm (NoMorFilm)
Application to medical devices
http://www.nomorfilm.euCOMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
https://www.imi.europa.eu/content/combacte-carePrioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
HU-MEN (High frequency Ultrasound-based MENingitis screening)
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Xpatial-TB
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
WHIP3TB
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
https://clinicaltrials.gov/ct2/show/NCT02980016New antibacterial agents against 'Acinetobacter baumannii'
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Development of New Metalloantibiotics Against Pathogens Associated to Chronic Infections in Cystic Fibrosis Patients
VINCI
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
INTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
http://inteafrica.org/AVATAR
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
SAFE - Superbug Awareness For Education
https://safeinitiative.eu/COVID-PREG
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo